Predictive IHC assay
VENTANA PD-L1 predictive assays identify patients who are most likely to respond to specific therapies, generating results you can trust so that you can make timely diagnostic decisions and therapeutic choices. We support your expertise by providing you with the tools that you need to successfully implement these assays into your laboratory and interpret them proficiently.
VENTANA PD-L1 (SP142) Assay gives you the confidence to appropriately identify urothelial carcinoma (UC) and non-small cell lung cancer (NSCLC) patients most likely to benefit from TECENTRIQ® (atezolizumab).
Using the right test to determine PD-L1 status for immunotherapy options is important. VENTANA PD-L1 (SP142) Assay is the first and only approved test for TECENTRIQ in urothelial carcinoma (UC) patients. This novel assay is also the first to evaluate patient PD-L1 expression using immune cell staining and scoring within the tumor microenvironment, providing you with information that can guide immunotherapy decisions.
VENTANA PD-L1 (SP142) Assay:
Using the right test to determine PD-L1 status for immunotherapy options is important, and the VENTANA PD-L1 (SP142) Assay is the only approved test for TECENTRIQ. This innovative assay is the first to evaluate patient PD-L1 expression using both tumor cell (TC) and tumor-infiltrating immune cell (IC) staining. Determining a patient’s PD-L1 expression level can give insight to the overall survival that may be achieved from TECENTRIQ.*
VENTANA PD-L1 (SP142) Assay:
*All randomized patients in a NSCLC phase III study observed benefit from TECENTRIQ regardless of PD-L1 status.
VENTANA PD-L1 (SP142) Assay is intended for the immunohistochemical assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor-infiltrating immune cells in formalin-fixed, paraffin-embedded (FFPE) tumor tissue stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a VENTANA BenchMark IHC/ISH instrument.
Determination of PD-L1 status is indication-specific and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity. PD-L1 expression may be associated with improved patient outcomes observed in clinical trials. See the TECENTRIQ® (atezolizumab) product label for the significance of PD-L1 expression levels in specific clinical settings.
PD-L1 expression in IC determined by VENTANA PD-L1 (SP142) Assay in urothelial carcinoma tissue may be associated with increased objective response rate (ORR).
PD-L1 expression in TC or IC determined by VENTANA PD-L1 (SP142) Assay in NSCLC tissue may be associated with enhanced overall survival.
This product is intended for in vitro diagnostic (IVD) use.